TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07243379: A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 495 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,827,200

Rescue Site Savings

+$7,798,560

Unlock Full NCT07243379 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07243379 Rescue Dossier →